Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:32:54.673Z.
Calculation as of: 2026-10-06T16:32:54.673Z.
Quote observation: 2026-10-06T16:29:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc2e94c8beea8e322b310e9b25a1b89028fd55b2fc6a2790cf1d230843e32158
PE RATIO
N/A
Market Cap
$39.08M
PE Ratio
N/A
TTM Avg
328.93
3Y Avg
271.56
5Y Avg
151.89
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $38.05M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.33M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.08M | N/A | 328.93 | 271.56 | 151.89 |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.76M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.42M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $39.96M | 23.19 | 36.35 | 61.12 | 61.12 |
| DocGo Inc. (DCGO)vs › | $35.92M | N/A | 14.70 | 37.22 | 37.36 |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.36M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.15M | 0.85 | 1.13 | 1.13 | 1.13 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
